Completed PHASE1 INTERVENTIONAL 1-arm NCT04710407

Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

A Phase 1, Single-center, Open-label Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

Sponsor: Clinartis

Conditions Healthy Volunteers

Interventions TBPM-PI-HBr

Updated 4 times since 2021 Last updated: Mar 15, 2021 Started: Dec 7, 2020 Primary completion: Mar 10, 2021 Completion: Mar 10, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04710407, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Clinartis, it has been updated 4 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2021 — Apr 2021 [monthly]

Recruiting PHASE1

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinartis
Spero Therapeutics

Data source: Spero Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Phoenix, United States